Home » Stocks » XFOR

X4 Pharmaceuticals, Inc. (XFOR)

Stock Price: $8.50 USD 0.35 (4.29%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $8.64 +0.14 (1.65%) Jan 15, 7:45 PM
Market Cap 138.44M
Revenue (ttm) 3.00M
Net Income (ttm) -54.57M
Shares Out 20.09M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $8.50
Previous Close $8.15
Change ($) 0.35
Change (%) 4.29%
Day's Open 8.08
Day's Range 8.08 - 8.70
Day's Volume 73,517
52-Week Range 5.41 - 11.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 1 week ago

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

Zacks Investment Research - 4 weeks ago

X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 1 month ago

BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 1 month ago

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 2 months ago

BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

Seeking Alpha - 2 months ago

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysf...

GlobeNewsWire - 2 months ago

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 3 months ago

BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 3 months ago

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from d...

GlobeNewsWire - 4 months ago

Manuscript further details positive clinical results and long-term tolerability of mavorixafor in ongoing Phase 2 study

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from ...

Seeking Alpha - 5 months ago

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from ...

GlobeNewsWire - 7 months ago

Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshol...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from ...

InvestorPlace - 7 months ago

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

Other stocks mentioned: BTG, CSTM, DVAX, INVE, LIVX, OVID, PLUG, SQNS, VG
GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:  XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...

Zacks Investment Research - 8 months ago

Arsanis Inc (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 8 months ago

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

X4 Pharmaceuticals, Inc. (C) CEO Paula Ragan on Q4 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...

Other stocks mentioned: CDMO, ENDP, IGMS, ILMN, ISEE, KOD, MYL, NVCN, PCRX, PFE

About XFOR

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström m... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Dr. Paula Ragan
Employees
68
Stock Exchange
NASDAQ
Ticker Symbol
XFOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price forecast is 18.75, which is an increase of 120.59% from the latest price.

Price Target
$18.75
(120.59% upside)
Analyst Consensus: Strong Buy